en
Scientific article
English

FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion

Published inInternational Journal of Cardiology, vol. 202, p. 52-58
Publication date2016
Abstract

A novel formulation of bosentan was evaluated in children with pulmonary arterial hypertension (PAH) in FUTURE-1, which characterized its pharmacokinetic and clinical profile. The subsequent phase III, open-label, long-term extension study, FUTURE-2, aimed to provide long-term tolerability, safety and exploratory efficacy data.

Keywords
  • Administration, Oral
  • Adult
  • Biomarkers, Pharmacological/metabolism
  • Dose-Response Relationship, Drug
  • Drug Tolerance
  • Endothelin Receptor Antagonists/administration & dosage/pharmacokinetics
  • Familial Primary Pulmonary Hypertension/drug therapy/metabolism/mortality
  • Female
  • Follow-Up Studies
  • Global Health
  • Humans
  • Male
  • Sulfonamides/administration & dosage/pharmacokinetics
  • Survival Rate/trends
  • Time Factors
  • Treatment Outcome
Citation (ISO format)
BERGER, Rolf M F et al. FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion. In: International Journal of Cardiology, 2016, vol. 202, p. 52–58. doi: 10.1016/j.ijcard.2015.08.080
Main files (2)
Article (Published version)
accessLevelRestricted
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0167-5273
339views
0downloads

Technical informations

Creation2017/09/14 12:10:00
First validation2017/09/14 12:10:00
Update time2023/03/15 02:00:08
Status update2023/03/15 02:00:07
Last indexation2024/01/17 00:38:40
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack